MiNK Therapeutics(INKT)
$8.84-0.45 (-4.79%)
INKT
MiNK Therapeutics financials statements
$8.84
At close:-0.45 (-4.79%)
Want to see INKT full AI Analyst Report?
MiNK Therapeutics (INKT) Ratios
274 Followers
MiNK Therapeutics Ratios
INKT's free cash flow for Q3 2026 was $-5.09B. For the 2026 fiscal year, INKT's free cash flow was increased by $0.00 and operating cash flow was $-5.09B. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.06 | 0.72 | 0.32 | 1.61 | 2.41 |
| Quick Ratio | 1.06 | 0.72 | 0.32 | 1.61 | 2.41 |
| Cash Ratio | 1.03 | 0.66 | 0.30 | 1.55 | 2.36 |
| Solvency Ratio | -0.43 | -0.42 | -0.98 | -1.27 | -1.83 |
| Operating Cash Flow Ratio | -0.45 | -1.37 | -1.38 | -1.49 | -0.78 |
| Short-Term Operating Cash Flow Coverage | -1.14 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -14.62M | $ -20.32M | $ -19.01M | $ -1.47M | $ 23.17M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.36 | 0.86 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | -0.36 | -0.25 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | -0.57 | -0.34 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | -0.34 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -1.00 | -0.29 | -0.25 | -53.50 | 1.69 |
| Debt Service Coverage Ratio | -2.38 | 0.00 | 0.00 | -110.02 | -11.39 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -122.17 | -7.65 |
| Debt to Market Cap | 0.11 | 0.19 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.21 | 1.32 | 0.00 | 0.08 | 0.73 |
| Net Debt to EBITDA | 0.66 | -0.03 | 0.15 | 0.70 | 1.40 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 100.06% | 101.26% | 97.98% | 90.44% | 162.38% |
| Return on Assets (ROA) | -87.75% | -188.52% | -493.33% | -130.36% | -75.08% |
| Return on Equity (ROE) | 87.82% | 55.06% | 124.38% | 6975.08% | -127.07% |
| Return on Capital Employed (ROCE) | -1034.24% | 859.68% | 334.60% | -352.16% | -78.26% |
| Return on Invested Capital (ROIC) | -195.52% | 859.68% | 334.60% | -352.16% | -78.26% |
| Return on Tangible Assets | -87.75% | -188.52% | -493.33% | -130.36% | -75.08% |
| Earnings Yield | -26.24% | -41.33% | -61.08% | -31.85% | -20.24% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.05 | 0.08 | 0.05 | 0.02 | 0.03 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -6879.09 | -4622.22 | -6978.26 | -17457.19 | -14025.27 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 6879.09 | 4622.22 | 6978.26 | 17457.19 | 14025.27 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.39 | -2.55 | -4.59 | -5.60 | -3.83 |
| Free Cash Flow Per Share | -1.39 | -2.55 | -4.61 | -5.68 | -3.91 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -2388869.00 | -214.28 | -75.45 | -51.52 |
| Capital Expenditure Coverage Ratio | 0.00 | -2388869.00 | -214.28 | -75.45 | -51.52 |
| Operating Cash Flow Coverage Ratio | -1.14 | -1.94 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -12.45% | -36.62% | -43.07% | -21.75% | -8.76% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.81 | -2.40 | -1.64 | -3.14 | -4.94 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -3.35 | -1.33 | -2.04 | -219.00 | 6.28 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -8.04 | -2.73 | -2.32 | -4.60 | -11.42 |
| Price-to-Operating Cash Flow Ratio | -8.04 | -2.73 | -2.33 | -4.66 | -11.64 |
| Price-to-Earnings Growth (PEG) Ratio | -3.68 | 0.04 | 0.08 | 0.39 | -0.06 |
| Enterprise Value Multiple | -3.20 | -2.50 | -1.50 | -2.45 | -3.99 |
| Enterprise Value | 39.43M | 26.44M | 33.40M | 68.25M | 110.42M |
| EV to EBITDA | -3.20 | -2.50 | -1.50 | -2.45 | -3.99 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -6.65 | -2.77 | -2.11 | -3.57 | -8.44 |
| EV to Operating Cash Flow | -6.65 | -2.77 | -2.12 | -3.62 | -8.61 |
| Tangible Book Value Per Share | -3.33 | -5.23 | -5.25 | -0.12 | 7.10 |
| Shareholders’ Equity Per Share | -3.33 | -5.23 | -5.25 | -0.12 | 7.10 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.93 | -2.88 | -6.54 | -8.31 | -9.03 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.09 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.47 | 0.89 | 0.70 | 0.67 | 0.42 |
Currency in USD

